Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial

Andrew J. Armstrong, Ping Lin, Bertrand Tombal, Fred Saad, Celestia S. Higano, Anthony M. Joshua, Teresa Parli, Brad Rosbrook, Steve van Os, Tomasz M. Beer

    Research output: Contribution to journalArticle

    1 Scopus citations

    Abstract

    After >5 yr of follow-up, enzalutamide continued to demonstrate improved long-term survival despite placebo crossover and multiple subsequent effective therapies in asymptomatic or mildly symptomatic men with metastatic castration-resistant prostate cancer. We identify clinical risk groups with widely disparate long-term survival.

    Original languageEnglish (US)
    JournalEuropean Urology
    DOIs
    StateAccepted/In press - 2020

    Keywords

    • Enzalutamide
    • Metastatic castration-resistant prostate cancer
    • Multivariable model
    • Overall survival
    • Prostate-specific antigen
    • Safety

    ASJC Scopus subject areas

    • Urology

    Fingerprint Dive into the research topics of 'Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial'. Together they form a unique fingerprint.

  • Cite this